Showing 5991-6000 of 9078 results for "".
- Prospective Data Show Comparable Performance Between AI and Dermatologistshttps://practicaldermatology.com/news/prospective-data-show-comparable-performance-between-ai-and-dermatologists/2486375/A new systematic review and meta-analysis of prospective studies suggests artificial intelligence (AI) systems can achieve diagnostic performance comparable to dermatologists in melanoma detection using dermoscopy. Investigato
- New Grants Expand Teledermatology Access in the Bronx and Los Angeleshttps://practicaldermatology.com/news/new-gwpfizer-grants-expand-teledermatology-access-in-the-bronx-and-los-angeles/2486357/The George Washington University School of Medicine (GW) and Health Sciences, in collaboration with Pfizer Global Medical Grants, has awarded 2 new grants to expand teledermatology services in underserved US communities, with 2026 programs set for the Bronx and Los
- Study: Potential Link Between Lesional IgG Autoantibodies and HS Disease Severityhttps://practicaldermatology.com/news/study-suggests-potential-link-between-lesional-igg-autoantibodies-and-hs-disease-severity/2486348/A small biopsy-based study in the Journal of Investigative Dermatology Innovations adds to emerging evidence that humoral immunity may contribute to hidradenitis suppurativa (HS) pathobiology. Investigators analyzed
- Analysis: Long Waits for Pediatric Dermatology Appointments Across UShttps://practicaldermatology.com/news/study-finds-long-waits-for-pediatric-dermatology-appointments-across-us/2486313/Children seeking dermatologic care in the US face long waits regardless of where they are referred, according to a research letter published online in JAMA Dermatology. Using a mystery caller design, investigators as
- Sotyktu Gets FDA Nod as First TYK2 Inhibitor for Psoriatic Arthritishttps://practicaldermatology.com/news/sotyktu-gains-fda-approval-as-first-tyk2-inhibitor-for-psoriatic-arthritis/2486046/The US Food and Drug Administration (FDA) has approved deucravacitinib (Sotyktu; Bristol Myers Squibb) for the treatment of adults with active psoriatic arthritis (PsA), representing the first oral therapy in its class approved for the treatment of the condition, a
- INTEGUMENT-OLE Data Show Sustained Efficacy of Roflumilast in Early Childhood ADhttps://practicaldermatology.com/news/integument-ole-data-show-sustained-efficacy-of-roflumilast-in-early-childhood-ad/2486045/The 56-week phase 3 open-label extension for the INTEGUMENT trial (INTEGUMETN-OLE) indicated once-daily roflumilast cream 0.05% maintained efficacy and demonstrated favorable long-term safety in children aged 2 to 5 years with mild-to-moderate atopic dermatitis (AD
- Baricitinib, Ritlecitinib, and Deuruxolitinib Demonstrate Efficacy in Severe AAhttps://practicaldermatology.com/news/baricitinib-ritlecitinib-and-deuruxolitinib-demonstrate-efficacy-in-severe-aa/2485957/An analysis of clinical trials reports that Janus kinase (JAK) inhibitors shows significant efficacy and manageable safety profiles in treating severe alopecia areata (AA). Alopecia areata (AA) is an autoimmune disorder charac
- Arcutis Launches First-in-Human Trial of CD200R Agonist ARQ-234 in Atopic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-first-in-human-trial-of-cd200r-agonist-arq-234-in-atopic-dermatitis/2485894/Arcutis Biotherapeutics announced today that it has enrolled the first participant in a phase 1a/1b clinical trial evaluating ARQ-234, an investigational CD200 receptor (CD200R) agonist, in healthy volunteers and adults with moderate to severe atopic dermatitis (AD
- EMA Panel Backs Baricitinib for Adolescents With Severe Alopecia Areatahttps://practicaldermatology.com/news/ema-panel-backs-baricitinib-for-adolescents-with-severe-alopecia-areata/2485850/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of baricitinib (Olumiant, Eli Lilly and Company), a once-daily oral Janus kinase (JAK) inhibitor, for adolescents aged 12 to yo
- Analysis: Tapinarof Cream Yields Improved Sleep in Pediatric ADhttps://practicaldermatology.com/news/analysis-links-tapinarof-cream-to-early-sleep-improvements-in-pediatric-ad/2485802/A new analysis of the phase 3 ADORING 1 and ADORING 2 trials showed that tapinarof cream, 1% (VTAMA, Organon) was associated with early and sustained improvements in sleep-related patient-reported outcomes in pediatric patients with moderate to severe atopic derma